We are live on ! Find out more
BGM

Burkehill Global Management Portfolio holdings

AUM $2.02B
1-Year Est. Return 85.32%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+85.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$498M
Cap. Flow
+$466M
Cap. Flow %
23.08%
Top 10 Hldgs %
41.93%
Holding
218
New
58
Increased
7
Reduced
12
Closed
36

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$147M
2
DLR icon
Digital Realty Trust
DLR
+$128M
3
FANG icon
Diamondback Energy
FANG
+$114M
4
NRG icon
NRG Energy
NRG
+$70.8M
5
SNDK
Sandisk
SNDK
+$70.6M

Top Sells

Rank Stock Value
1
ITT icon
ITT
ITT
+$60.7M
2
SOFI icon
SoFi Technologies
SOFI
+$52.4M
3
NDAQ icon
Nasdaq
NDAQ
+$48.6M
4
EL icon
Estee Lauder
EL
+$47.1M
5
ROL icon
Rollins
ROL
+$43.5M

Sector Composition

Rank Sector Weight
1 Healthcare 22.71%
2 Technology 19.4%
3 Industrials 18.69%
4 Energy 10.65%
5 Real Estate 8.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLGO
101
Pelagos Insurance Capital
PLGO
$2.19B
$2.87M 0.14%
150,000
– –
DYN icon
102
Dyne Therapeutics
DYN
$4.04B
$2.81M 0.14%
155,000
– –
VOYG
103
Voyager Technologies
VOYG
$1.5B
$2.81M 0.14%
120,000
– –
IMMX icon
104
Immix Biopharma
IMMX
$607M
$2.68M 0.13%
294,118
– –
FDMT icon
105
4D Molecular Therapeutics
FDMT
$526M
$2.56M 0.13%
275,000
– –
APGE icon
106
Apogee Therapeutics
APGE
$10.2B
$2.53M 0.13%
+30,000
New +$2.18M
AERO
107
Grupo Aeromexico SAB de CV
AERO
$2.18B
$2.45M 0.12%
175,000
– –
TARA icon
108
Protara Therapeutics
TARA
$226M
$2.34M 0.12%
450,000
– –
METC icon
109
Ramaco Resources Class A
METC
$676M
$2.32M 0.12%
150,000
– –
AVBP icon
110
ArriVent BioPharma
AVBP
$1.48B
$2.31M 0.11%
100,000
– –
VIA
111
Via Transportation Inc
VIA
$1.44B
$2.25M 0.11%
150,000
– –
TE
112
T1 Energy
TE
$1.4B
$2.19M 0.11%
500,000
– –
SHC icon
113
Sotera Health
SHC
$4.95B
$2.15M 0.11%
150,000
– –
NTSK
114
Netskope Inc
NTSK
$4.66B
$2.12M 0.11%
250,000
– –
TERN
115
DELISTED
Terns Pharmaceuticals
TERN
$2.11M 0.1%
40,000
– –
BCAX
116
Bicara Therapeutics
BCAX
$1.78B
$1.99M 0.1%
+100,000
New +$1.72M
RDW icon
117
Redwire
RDW
$2.08B
$1.91M 0.09%
225,000
– –
AKR icon
118
Acadia Realty Trust
AKR
$2.99B
$1.91M 0.09%
100,000
– –
DFTX
119
Definium Therapeutics
DFTX
$5.73B
$1.89M 0.09%
100,000
– –
CABA icon
120
Cabaletta Bio
CABA
$439M
$1.88M 0.09%
700,000
– –
OLMA icon
121
Olema Pharmaceuticals
OLMA
$1.02B
$1.86M 0.09%
125,000
– –
NRIX icon
122
Nurix Therapeutics
NRIX
$2.43B
$1.84M 0.09%
118,972
– –
STRO icon
123
Sutro Biopharma
STRO
$379M
$1.78M 0.09%
+71,530
New +$1.29M
AVAH icon
124
Aveanna Healthcare
AVAH
$2.06B
$1.77M 0.09%
275,000
– –
BIOA
125
BioAge Labs
BIOA
$968M
$1.75M 0.09%
+100,000
New +$1.93M
3 4
5
6 7

Similar funds

AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
NIM
NXG Investment Management Dallas, Texas $2.02B AUM 30.38% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.03B AUM 32.21% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.03B AUM 26.86% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Burkehill Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Burkehill Global Management held 218 positions worth $2.02B, up 33% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Burkehill Global Management deployed $466M of net new capital in Q1 2026, opening 58 new positions and adding to 7 existing holdings. Its largest new stake was Eli Lilly: 145,000 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 19% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Nebius Group N.V., an estimated $22.5M trimmed.

  • Burkehill Global Management's largest Q1 2026 buy was Eli Lilly: 145,000 shares worth $133M.
  • Burkehill Global Management added most to Medline Inc in Q1 2026, an estimated $43.4M increase.
  • Burkehill Global Management's biggest Q1 2026 reduction was Nebius Group N.V., cutting an estimated $22.5M.
  • Burkehill Global Management fully exited ITT in Q1 2026, selling an estimated $60.7M.
  • Burkehill Global Management's ten largest holdings make up 42% of its $2.02B portfolio in Q1 2026.
  • Burkehill Global Management opened 58 new positions and closed 36 in Q1 2026.
  • Burkehill Global Management's portfolio value rose 33% quarter-over-quarter to $2.02B.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.